2014 May 6. pii: S0968-0896(14)00331-9. doi: 10.1016/j.bmc.2014.04.057. [Epub ahead of print]
Identification and characterization of a new reversible MAGL inhibitor.
Tuccinardi T1, Granchi C2, Rizzolio F3, Caligiuri I3, Battistello V2, Toffoli G3, Minutolo F2, Macchia M2, Martinelli A2.
Abstract
Monoacylglycerol lipase is a serine hydrolase that play a major role in the degradation of 2-arachidonoylglycerol, an endocannabinoidneurotransmitter implicated in several physiological processes. Recent studies have shown the possible role of MAGL inhibitors as anti-inflammatory, anti-nociceptive and anti-cancer agents. The use of irreversible MAGL inhibitors determined an unwanted chronic MAGL inactivation, which acquires a functional antagonism function of the endocannabinoid system. However, the application of reversible MAGL inhibitors has not yet been explored, mainly due to the scarcity of known compounds possessing efficient reversible inhibitory activities. In this study we reported the first virtual screening analysis for the identification of reversible MAGL inhibitors. Among the screened compounds, the (4-(4-chlorobenzoyl)piperidin-1-yl)(4-methoxyphenyl)methanone (CL6a) is a promising reversible MAGL inhibitor lead (Ki=8.6μM), which may be used for the future development of a new class of MAGL inhibitors. Furthermore, the results demonstrate the validity of the methodologies that we followed, encouraging additional screenings of other commercial databases.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Copyright © 2014 Elsevier Ltd. All rights reserved.
KEYWORDS:
Hydrolase, MAGL, Monoacylglycerol lipase inhibitors, Virtual screening